09:07 AM EDT, 09/27/2024 (MT Newswires) -- Tonix Pharmaceuticals Holding ( TNXP ) said Friday it received a patent from the US Patent and Trademark Office for its pre-filled autoinjector comprising of Zembrace SymTouch composition to treat migraines.

The patent is anticipated to expire in 2036, excluding potential extensions, the biopharmaceutical company added.

Zembrace is a US Food and Drug Administration-approved treatment for migraines, Tonix said.

Shares of the company rose 23% in recent Friday premarket activity.

Price: 0.1685, Change: +0.03, Percent Change: +23.35